JP-163-16

JP-163-16 is a RelA/p65 PROTAC degrader. JP-163-16 selectively reduces the expression of RelA/p65 in a proteasome-dependent manner in cells. JP-163-16 can induce cell apoptosis by inhibiting the NF-κB signaling pathway. JP-163-16 can be used for research on RelA/p65-dependent tumours, such as chronic lymphocytic leukaemia (CLL) . (Pink: RelA/p65 Ligand (HY-174865) ; Blue: CRBN Ligand (HY-A0003) ; Black: Linker; CRBN Ligand+Linker (HY-160241) ) [1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; NF-κB; PROTACs

Related Pathways

Apoptosis; NF-κB; PROTAC

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

O=C(NC1=CC=C(NC(CCCOC2=C(OC)C=C3C(N=C[C@@](CCC4)([H])N4C3=O)=C2)=O)C=C1)CCCCCNC5=CC=CC6=C5CN(C(CC7)C(NC7=O)=O)C6=O

Molecular Formula

C42H47N7O8

Molecular Weight

777.86

References & Citations

[1]Jin P, et al. Design, synthesis and evaluation of pyrrolobenzodiazepine (PBD) -based PROTAC conjugates for the selective degradation of the NF-κB RelA/p65 subunit. RSC Med Chem. 2025 May 8.